Intrinsiqq

CellaVision AB (CEVI.XSTO) Quality Score

CEVI.XSTO
Quality54

Valuation is the primary weakness (avg 40/100). Business quality is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
30.3x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
40/100
39.8x

Above 30x, cash flow yield is thin

Revenue Growth
50/100
3.7%

2–5% CAGR, growing but slowly

Cash Flow Growth
70/100
9.7%

5–10% CAGR, steady but not exceptional

Business Quality & Capital Allocation

Share Dilution
80/100
-0.0%

Roughly flat, no meaningful dilution

Margin Trend
0/100
-2.5pp

Contracted >2pp, margin pressure

Capital Structure
100/100
-kr 163M

Net cash position, no leverage concern

2022
kr 108M
kr 102M
2023
kr 122M
kr 65M
2024
kr 149M
kr 27M
2025
kr 188M
kr 26M
Return on Capital
80/100
18.1%

15–20%, well above cost of capital

Customize WeightsPremiumUpgrade

CellaVision AB (CEVI.XSTO) quality: score, margins and returns

CellaVision AB (CEVI.XSTO) scores 54/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 22.2% operating margins and 18.1% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is CellaVision AB (CEVI.XSTO) a high-quality business?+

CellaVision AB scores 54 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 22.2% operating margin and a 18.1% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does CellaVision AB's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CEVI.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where CellaVision AB scores well and where it falls behind.

What is CellaVision AB's return on invested capital (ROIC)?+

CellaVision AB earns about 18.1% on its invested capital, which is strong. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CEVI.XSTO's margins and growth on this scorecard to judge durability.

How profitable is CellaVision AB?+

CellaVision AB runs an operating margin of about 22.2% and a net margin of about 17.5%. Revenue has grown at roughly 7.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on CEVI.XSTO: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Related stocks: Medical Devices

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.